Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Validation of diagnosis codes to identify side of colon in an electronic health record registry.

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker MG, Arnieri B, Taylor MD, Meropol NJ.

BMC Med Res Methodol. 2019 Aug 19;19(1):177. doi: 10.1186/s12874-019-0824-7.

2.

Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R.

Eur Urol. 2019 Oct;76(4):524-532. doi: 10.1016/j.eururo.2019.07.032. Epub 2019 Jul 28.

PMID:
31362898
3.

Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.

Steuten L, Goulart B, Meropol NJ, Pritchard D, Ramsey SD.

JCO Clin Cancer Inform. 2019 Jun;3:1-10. doi: 10.1200/CCI.19.00002.

4.

Development and validation of a model to predict outcomes of colon cancer surveillance.

Rose J, Homa L, Kong CY, Cooper GS, Kattan MW, Ermlich BO, Meyers JP, Primrose JN, Pugh SA, Shinkins B, Kim U, Meropol NJ.

Cancer Causes Control. 2019 Jul;30(7):767-778. doi: 10.1007/s10552-019-01187-x. Epub 2019 May 25.

PMID:
31129907
5.

Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Langer CJ, Vachani A.

J Natl Compr Canc Netw. 2019 May 1;17(5):469-477. doi: 10.6004/jnccn.2018.7102.

6.

Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.

Kim SP, Shah ND, Meropol NJ, Tilburt JC, Nguyen PL, Yu JB, Abouassaly R, Kim A, Gross CP.

Eur Urol Oncol. 2019 Mar;2(2):189-195. doi: 10.1016/j.euo.2018.08.004. Epub 2018 Aug 31.

PMID:
31017095
7.

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice.

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R.

Oncologist. 2019 Jun;24(6):e397-e399. doi: 10.1634/theoncologist.2019-0039. Epub 2019 Apr 3.

PMID:
30944183
8.

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC).

El-Deiry WS, Winer A, Slifker M, Taylor S, Adamson BJS, Meropol NJ, Ross EA.

Front Oncol. 2019 Mar 14;9:142. doi: 10.3389/fonc.2019.00142. eCollection 2019.

9.

Implementing an Electronic End-of-Life Chemotherapy Utilization Measure.

Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ.

J Oncol Pract. 2019 Apr;15(4):220-223. doi: 10.1200/JOP.18.00408. Epub 2019 Mar 18. No abstract available.

PMID:
30883256
10.

Opportunities for using big data to advance cancer care.

Meropol NJ.

Clin Adv Hematol Oncol. 2018 Dec;16(12):807-809. No abstract available.

PMID:
30843889
11.

A National Study of Oncology Nurses Discussing Cancer Clinical Trials With Patients.

Flocke SA, Nock NL, Fulton S, Margevicius S, Manne S, Meropol NJ, Daly BJ.

West J Nurs Res. 2019 Feb 19:193945919829145. doi: 10.1177/0193945919829145. [Epub ahead of print]

PMID:
30782111
12.

Surgical approach and the impact of epidural analgesia on survival after esophagectomy for cancer: A population-based retrospective cohort study.

Cummings Iii KC, Kou TD, Chak A, Schluchter MD, Margevicius S, Cooper GS, Meropol NJ, Perry Y, Linden PA, Cummings LC.

PLoS One. 2019 Jan 22;14(1):e0211125. doi: 10.1371/journal.pone.0211125. eCollection 2019. Erratum in: PLoS One. 2019 Mar 21;14(3):e0214528.

13.

Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists.

Kim SP, Gross CP, Shah ND, Tilburt JC, Konety B, Williams SB, Weight CJ, Yu JB, Kumar AMS, Meropol NJ.

Ann Surg Oncol. 2019 Feb;26(2):660-668. doi: 10.1245/s10434-018-6863-1. Epub 2018 Oct 11.

PMID:
30311161
14.

Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists.

Kim SP, Meropol NJ, Gross CP, Tilburt JC, Konety B, Yu JB, Abouassaly R, Weight CJ, Williams SB, Shah ND.

Urol Oncol. 2018 Nov;36(11):501.e15-501.e21. doi: 10.1016/j.urolonc.2018.07.002. Epub 2018 Sep 3.

PMID:
30190177
15.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
16.

Carcinoembryonic Antigen-Still More to Learn From the Real World.

Miksad RA, Meropol NJ.

JAMA Oncol. 2018 Mar 1;4(3):315-316. doi: 10.1001/jamaoncol.2017.4408. No abstract available.

PMID:
29270625
17.

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).

Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, Hall MJ, Saltzman JN, George TJ Jr, Zangmeister J, Chiorean EG, Cheema PS, O'Dwyer PJ, Benson AB 3rd.

Cancer. 2018 Feb 15;124(4):688-697. doi: 10.1002/cncr.30967. Epub 2017 Dec 6.

18.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

19.

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.

Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW.

Br J Cancer. 2018 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21.

20.

Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates.

Malek E, Saygin C, Ye R, Covut F, Kim BG, Welge J, Meropol NJ, De Lima M, Driscoll JJ.

JCO Clin Cancer Inform. 2017 Nov;1:1-14. doi: 10.1200/CCI.17.00055. Review.

21.

Relationship between phase I study duration and symptom burden.

Treasure M, Daly B, Fu P, Kerpedjieva S, Dowlati A, Meropol NJ.

Support Care Cancer. 2018 Mar;26(3):731-737. doi: 10.1007/s00520-017-3879-1. Epub 2017 Oct 5.

PMID:
28980072
22.

The Role of Oncology Nurses in Discussing Clinical Trials.

Flocke SA, Antognoli E, Daly BJ, Jackson B, Fulton SE, Liu TM, Surdam J, Manne S, Meropol NJ.

Oncol Nurs Forum. 2017 Sep 1;44(5):547-552. doi: 10.1188/17.ONF.547-552.

23.

Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort.

Chen VS, Abouassaly R, Gonzalez CM, Kutikov A, Smaldone MC, Meropol NJ, Psutka SP, Williams SB, O'Malley R, Sedlacek HM, Kim SP.

Urol Oncol. 2017 Nov;35(11):662.e17-662.e21. doi: 10.1016/j.urolonc.2017.07.011. Epub 2017 Aug 7.

PMID:
28781110
24.

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW.

Breast Cancer Res Treat. 2017 Sep;165(2):375-382. doi: 10.1007/s10549-017-4310-9. Epub 2017 Jun 16.

25.

A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy.

Enzinger AC, Wind JK, Frank E, McCleary NJ, Porter L, Cushing H, Abbott C, Cronin C, Enzinger PC, Meropol NJ, Schrag D.

Patient Educ Couns. 2017 Aug;100(8):1527-1536. doi: 10.1016/j.pec.2017.03.024. Epub 2017 Mar 22.

26.

Addressing Patients' Priorities as a Strategy to Improve Value.

Wong YN, Roach N, Meropol NJ.

Oncologist. 2016 Nov;21(11):1279-1282. doi: 10.1634/theoncologist.2016-0184. Epub 2016 Oct 14. No abstract available.

27.

Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.

Kim SP, Karnes RJ, Gross CP, Meropol NJ, Van Houten H, Abouassaly R, Shah ND.

Urology. 2016 Nov;97:111-117. doi: 10.1016/j.urology.2016.06.067. Epub 2016 Aug 12.

PMID:
27527411
28.

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.

Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, Jin Z, Dong B, Cao B, Feng X, Xiang M, Xu C, Fink S, Meropol NJ, Xu Y, Conlon RA, Markowitz S, Kinzler KW, Velculescu VE, Brunengraber H, Willis JE, LaFramboise T, Hatzoglou M, Zhang GF, Vogelstein B, Wang Z.

Nat Commun. 2016 Jun 20;7:11971. doi: 10.1038/ncomms11971.

29.

Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort.

Wang EH, Yu JB, Abouassally R, Meropol NJ, Cooper G, Shah ND, Williams SB, Gonzalez C, Smaldone MC, Kutikov A, Zhu H, Kim SP.

Urology. 2016 Sep;95:88-94. doi: 10.1016/j.urology.2016.06.010. Epub 2016 Jun 16.

PMID:
27318264
30.

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL.

J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31. No abstract available.

PMID:
27247218
31.

Health policy: Overcoming cost barriers to clinical trial participation.

Meropol NJ.

Nat Rev Clin Oncol. 2016 May 20;13(6):333-4. doi: 10.1038/nrclinonc.2016.72. No abstract available.

PMID:
27199178
32.

Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.

Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ, Astsaturov I, McAleer C, Fittipaldi P, Thrash-Bingham C, Meropol NJ, Cohen SJ.

Pancreas. 2016 Sep;45(8):1131-5. doi: 10.1097/MPA.0000000000000619.

33.

Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort.

Kiechle JE, Abouassaly R, Gross CP, Dong S, Cherullo EE, Zhu H, Trinh QD, Sun M, Meropol NJ, Hoimes CJ, Ialacci S, Kim SP.

Urology. 2016 Apr;90:69-74. doi: 10.1016/j.urology.2015.10.035. Epub 2015 Dec 24.

PMID:
26724412
34.

Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials.

Meropol NJ, Wong YN, Albrecht T, Manne S, Miller SM, Flamm AL, Benson AB 3rd, Buzaglo J, Collins M, Egleston B, Fleisher L, Katz M, Kinzy TG, Liu TM, Margevicius S, Miller DM, Poole D, Roach N, Ross E, Schluchter MD.

J Clin Oncol. 2016 Feb 10;34(5):469-78. doi: 10.1200/JCO.2015.63.2257. Epub 2015 Dec 23.

35.

Financial Concerns About Participation in Clinical Trials Among Patients With Cancer.

Wong YN, Schluchter MD, Albrecht TL, Benson AB 3rd, Buzaglo J, Collins M, Flamm AL, Fleisher L, Katz M, Kinzy TG, Liu TM, Manne S, Margevicius S, Miller DM, Miller SM, Poole D, Raivitch S, Roach N, Ross E, Meropol NJ.

J Clin Oncol. 2016 Feb 10;34(5):479-87. doi: 10.1200/JCO.2015.63.2463. Epub 2015 Dec 23.

36.

A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

Eads JR, Beumer JH, Negrea L, Holleran JL, Strychor S, Meropol NJ.

Cancer Chemother Pharmacol. 2016 Feb;77(2):333-8. doi: 10.1007/s00280-015-2939-9. Epub 2015 Dec 21.

37.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

38.

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL, American Society of Clinical Oncology.

J Clin Oncol. 2015 Aug 10;33(23):2563-77. doi: 10.1200/JCO.2015.61.6706. Epub 2015 Jun 22. No abstract available.

39.

Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses.

Tabayoyong W, Abouassaly R, Kiechle JE, Cherullo EE, Meropol NJ, Shah ND, Dong S, Thompson RH, Smaldone MC, Zhu H, Ialacci S, Kim SP.

J Urol. 2015 Dec;194(6):1548-53. doi: 10.1016/j.juro.2015.06.076. Epub 2015 Jun 19.

PMID:
26094808
40.

Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.

Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS.

Am Soc Clin Oncol Educ Book. 2015:e222-7. doi: 10.14694/EdBook_AM.2015.35.e222. Review.

41.

Comparative effectiveness of screening strategies for Lynch syndrome.

Barzi A, Sadeghi S, Kattan MW, Meropol NJ.

J Natl Cancer Inst. 2015 Mar 20;107(4). pii: djv005. doi: 10.1093/jnci/djv005. Print 2015 Apr.

42.

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.

von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB.

Cancer Chemother Pharmacol. 2015 May;75(5):1047-55. doi: 10.1007/s00280-015-2705-z. Epub 2015 Mar 20.

43.

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.

Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV.

Br J Cancer. 2015 Mar 31;112(7):1199-205. doi: 10.1038/bjc.2015.73.

44.

Trial prospector: matching patients with cancer research studies using an automated and scalable approach.

Sahoo SS, Tao S, Parchman A, Luo Z, Cui L, Mergler P, Lanese R, Barnholtz-Sloan JS, Meropol NJ, Zhang GQ.

Cancer Inform. 2014 Dec 4;13:157-66. doi: 10.4137/CIN.S19454. eCollection 2014.

45.

Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.

Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):116-23. doi: 10.1016/j.ijrobp.2014.09.031. Epub 2014 Nov 5.

46.

Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.

Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, McSpadden E, Choi M, Adaire B, Duncan G, Meropol NJ, Cescon TP, Cohen SJ.

Radiother Oncol. 2014 Oct;113(1):35-40. doi: 10.1016/j.radonc.2014.08.014. Epub 2014 Oct 20.

PMID:
25441058
47.

Payment for cancer care: time for a new prescription.

Schnipper LE, Meropol NJ.

J Clin Oncol. 2014 Dec 20;32(36):4027-8. doi: 10.1200/JCO.2014.57.9573. Epub 2014 Nov 3. No abstract available.

PMID:
25366682
48.

Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.

Dotan E, Li T, Hall MJ, Meropol NJ, Beck JR, Wong YN.

J Oncol Pract. 2014 Sep;10(5):308-14. doi: 10.1200/JOP.2014.001439. Epub 2014 Jul 22.

49.

Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.

Cohen SJ, Konski AA, Putnam S, Ball DS, Meyer JE, Yu JQ, Astsaturov I, Marlow C, Dickens A, Cade DN, Meropol NJ.

Br J Cancer. 2014 Jul 15;111(2):265-71. doi: 10.1038/bjc.2014.344. Epub 2014 Jul 1.

50.

Current status of gene expression profiling to assist decision making in stage II colon cancer.

Chee CE, Meropol NJ.

Oncologist. 2014 Jul;19(7):704-11. doi: 10.1634/theoncologist.2013-0471. Epub 2014 May 28.

Supplemental Content

Loading ...
Support Center